Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP:BAYRY)

8.090 +0.350 (+4.52%)
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,313,640
Open 8.270
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 7.740
Today's Range 8.050 - 8.310
52wk Range 4.790 - 8.650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports
The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and... 
Via MarketMinute
Topics Artificial Intelligence

Performance

YTD
+63.8%
+63.8%
1 Month
+3.6%
+3.6%
3 Month
+25.0%
+25.0%
6 Month
+41.7%
+41.7%
1 Year
+8.4%
+8.4%

More News

Read More
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
Via Benzinga
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug
Via Investor's Business Daily
OTC Markets Group Welcomes Bayer AG to OTCQX
From OTC Markets
Via GlobeNewswire
Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure
Via Benzinga
FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation
Via Benzinga
Bayer Enters License Agreement With China’s Puhe BioPharma For Cancer Drug Candidate: Retail Stays Bullish
Via Stocktwits
Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards
Via Benzinga
Topics Earnings
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
Via Benzinga
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Via Benzinga
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Via Benzinga
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Via MarketBeat
Bayer Seeks European Approval For Its Menopause Drug
Via Benzinga
Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide
Via Benzinga
Week In Review: Zenas Raises $259 Million In IPO
Via Talk Markets
Topics Initial Public Offering
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
Via Investor's Business Daily
“Signing Day Sports, Inc. (NYSE American: SGN) Soars in Pre-Market on Acquisition News – see more penny stocks inside….”
Via AB Newswire
Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study
Via Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Via Benzinga
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
Via Benzinga
BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer
Via Benzinga
Topics Lawsuit
ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
Via MarketBeat
Topics Cannabis
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
Via InvestorPlace

Frequently Asked Questions

Is Bayer Aktienges ADR publicly traded?
Yes, Bayer Aktienges ADR is publicly traded.
What exchange does Bayer Aktienges ADR trade on?
Bayer Aktienges ADR trades on the OTC Traded
What is the ticker symbol for Bayer Aktienges ADR?
The ticker symbol for Bayer Aktienges ADR is BAYRY on the OTC Traded
What is the current price of Bayer Aktienges ADR?
The current price of Bayer Aktienges ADR is 8.090
When was Bayer Aktienges ADR last traded?
The last trade of Bayer Aktienges ADR was at 08/01/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.